Moderate IMRT dose reduction feasible in T1-3 nasopharynx cancer

  • Wang X & al.
  • J Cancer
  • 1 Jan 2019

  • curated by Brian Richardson, PhD
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Intensity modulated radiotherapy (IMRT) with a median dose of 63.6 Gy was associated with similar locoregional failure-free survival (LRFS), distant metastasis-free survival (DMFS), disease-free survival (DFS), and OS as the standard dose of 70 Gy in patients with T1-3 nasopharyngeal carcinoma (NPC).

Why this matters

  • Lower radiation doses are associated with reduced toxicity.

Key results

  • In the entire cohort, 5-year LRFS was 93.6%, 5-year DMFS was 85.5%, 5-year DFS was 77.9%, and 5-year OS was 81.8%.
  • In propensity score-matched analysis, patients who received a radiation dose
  • LRFS (92.5% vs 91.7%; P=.863).
  • DMFS (89.5% vs 88.1%; P=.947).
  • DFS (75.9% vs 82.1%; P=.469).
  • OS (82.1% vs 85.7%; P=.869).

Study design

  • 266 patients with T1-3 NPC treated with IMRT were included.
  • Propensity score matching identified 32 patients treated with a de-escalated dose (
  • Funding: National Natural Science Foundation of China.

Limitations

  • Retrospective design.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit